Role of Sodium Nitroprusside in Primary PCI

Body of Paper

Sodium nitroprusside (Na2[Fe(CN)5NO]·2H2O), commonly abbreviated as SNP, is a red-colored salt known for its potent vasodilator properties. It is administered intravenously during emergencies requiring acute hypertension management [1].

Historically, sodium nitroprusside has been primarily used in diagnostic procedures for detecting sulphur dioxide, acetone, aldehydes, and alkali sulphides. Its use in suicides by medical and nursing staff has also been noted, with cyanogen (prusside) as the primary cause of death due to the decomposition of nitroprusside [2]. Research on its hypotensive effects has been limited, with Johnson’s study indicating that parenteral nitroprusside’s effect is 50–1000 times stronger than the nitrite ion, noting a depressant-to- hazardous dosage ratio of 1:10 [3].

Sodium nitroprusside features an octahedral ferrous center surrounded by five cyanide ligands and one nitric oxide ligand, giving it the molecular symmetry C4v. Upon dissolving in water, it yields the dianion [Fe(CN)5NO]-2. In the bloodstream, SNP decomposes to release nitric oxide (NO), which has strong vasodilating effects on arterioles and venules. This process involves the conversion of haemoglobin to cyanmethemoglobin and the subsequent excretion of thiocyanate in the urine. NO activates guanylate cyclase in vascular smooth muscle, increasing intracellular cGMP levels and leading to the relaxation of vascular smooth muscle [4].

Nitroprusside is notably effective for treating acute hypertensive situations due to its favorable hemodynamic profile and rapid action onset and cessation (3-5 minutes). It is administered via continuous intravenous infusion at doses of 0.25–10 µg/kg/min in intensive care settings, with close monitoring of arterial blood pressure. Hemodynamic effects include reduced mean arterial pressure, afterload, and preload, which can improve cardiac output and renal blood flow [5].

Nitroprusside reduces venous return and total peripheral resistance, lowering preload and afterload, and can be used in severe cardiogenic heart failure to enhance cardiac output. Studies have shown that nitroprusside can improve left ventricular function and reduce myocardial oxygen demand in patients with ischemic heart disease-related congestive heart failure [6].

Short-term benefits on left ventricular function and regional ischemic myocardium have also been noted during acute myocardial infarction [7]. Early studies indicated that nitroprusside reduces precordial ST segment elevation and mortality in acute myocardial infarction patients and increases coronary collateral flow [8, 9]. However, there is evidence suggesting that nitroprusside may increase ischemic injury in some patients by redistributing blood away from the ischemic myocardium, a phenomenon known as “coronary steal” [10].

Studies on intracoronary nitroprusside during angioplasty, stent deployment, or rotational atherectomy have demonstrated significant, rapid, and safe improvement of no-reflow, with no significant hypotension or adverse clinical events reported [11]. In a study on 23 patients, nitroprusside significantly improved coronary flow and TIMI flow grade, with transient hypotension as the only significant adverse effect [12].

Another study showed that intracoronary bolus injection of nitroprusside improved angiographic TIMI flow in 82% of patients without adverse effects [13].

However, a study found that while intracoronary nitroprusside before primary angioplasty did not improve coronary flow and myocardial tissue perfusion, it did improve clinical outcomes at six months [14]. Additionally, nitroprusside was found to produce a sustained coronary hyperemic response equivalent to adenosine without detrimental systemic hemodynamics [15].

The Reopen-AMI study on 240 patients undergoing primary or rescue PCI with thrombus aspiration compared the efficacy and safety of intracoronary nitroprusside versus adenosine as adjunctive treatments. This study provided important data on their use in patients with acute myocardial infarction [16].